目的 分析蚌埠市第三人民醫(yī)院婦產(chǎn)科門診超說明書用藥情況，為促進合理用藥提供參考。方法 通過合理用藥軟件隨機等間距抽取2022年4月1日至2024年3月31日蚌埠市第三人民醫(yī)院婦產(chǎn)科門診處方7 200張，篩選出超說明書用藥的處方，并基于循證醫(yī)學證據(jù)對超說明用藥處方進行合理性評價和分析。結(jié)果 隨機抽取的7 200張婦產(chǎn)科門診處方，超說明書用藥的處方364張，超說明書用藥處方占比為5.06%，共涉及甲硝唑片、米索前列醇片等在內(nèi)的12種藥品，其中超給藥途徑處方為241張，占比66.21%，超適應證處方105張，占比28.84%，超劑量處方18張，占比4.95%。226張?zhí)幏匠f明書用藥無高級別循證醫(yī)學證據(jù)支持，判定為不合理處方，占比62.09%。結(jié)論 蚌埠市第三人民醫(yī)院婦產(chǎn)科門診處方存在超說明書用藥的現(xiàn)象，臨床確需超說明書用藥時應充分權(quán)衡利弊，建立相應的超說明書用藥管理制度與流程，盡量規(guī)避醫(yī)療風險，保證臨床用藥安全。

Objective To analyze the situation of off-label drug use in obstetrics and gynecology outpatient of The Third the People’s Hospital of Bengbu, to provide reference for promoting rational drug use. Methods Through the rational drug use software, 7 200 prescriptions of the obstetrics and gynecology outpatient department of The Third People’s Hospital Bengbu from April 1, 2022 to March 31, 2024 were randomly selected at equal intervals, and the prescriptions of off-label drug use were screened out, and the rationality of the prescriptions of off-label drug use was evaluated and analyzed based on evidence-based medical evidence. Results Among the 7 200 prescriptions randomly selected in obstetrics and gynecology outpatient clinics, 364 were off-label drug use, accounting for 5.06%, involving a total of 12 kinds of drugs, including Metronidazole Tablets, Misoprostol Tablets, among which Among them, there were 241 prescriptions of over-dose route, accounting for 66.21%, 105 prescriptions of over-indication, accounting for 28.84%, and 18 prescriptions of over-dose, accounting for 4.95%. 226 (62.09%) prescriptions of off-label drug use were not supported by high-level evidence-based medical evidence, and were judged as unreasonable prescriptions. Conclusion The phenomenon of off-label drug use exists in the obstetrics and gynecology outpatient prescriptions of The Third People’s Hospital Bengbu. When off-label drug use is really needed in clinic, the pros and cons should be fully weighed, and corresponding off-label drug use management system and process should be established to avoid medical risks as far as possible and ensure clinical drug safety.

R984